Objective: The aim of this study was to analysis raltitrexed by the safety and efficacy of intra-arterial infusion chemotherapy. Methods: Forty-seven cases in different parts of cancer patients, interventional methods, based on digital subtraction angiography(DSA) prompt, raltitrexed-based chemotherapy, the tumor nourish artery infusion chemotherapy.Patients with postoperative chemotherapy side effects and complications, and efficacy assessments. Results: Forty-seven patients, 2 patients had II-III degree of bone marrow suppression, the rate was 4.26%, 34 cases of I to II degree gastrointestinal reactions, 1 case of grade III gastrointestinal reactions, the incidence of 2.13%, and 1 case mild diarrhea. I degrees or more chemotherapy-related adverse reactions did not occur in this group of patients. All patients received at least 2 times arterial infusion chemotherapy, complete remission(CR) 3 cases, partial remission(PR) 11 cases, stable disease(SD) 17cases, disease progression(PD) 6 cases, total effective rate of treatment 87.23%. Conclusion: Raltitrexed for intra-arterial chemotherapy is safe and effective. However, due to the small number of this group of patients, time is short, its safety, efficacy and long-term efficacy needs further observation and validation. Objective: The aim of this study was to analysis raltitrexed by the safety and efficacy of intra-arterial infusion chemotherapy. Methods: Forty-seven cases in different parts of cancer patients, interventional methods, based on digital subtraction angiography (DSA) prompt, raltitrexed -based chemotherapy, the tumor nourish artery infusion chemotherapy. Patients with postoperative chemotherapy side effects and complications, and efficacy assessments. Results: Forty-seven patients, 2 patients had II-III degree of bone marrow suppression, the rate was 4.26%, 34 Cases of I to II degree gastrointestinal reactions, 1 case of grade III gastrointestinal reactions, the incidence of 2.13%, and 1 case mild diarrhea. I degrees or more chemotherapy-related adverse reactions did not occur in this group of patients. All patients received at least 2 times arterial infusion chemotherapy, complete remission (CR) 3 cases, partial remission (PR) 11 cases, stable disease (SD) 17cases, disease progression However, due to the small number of this group of patients, time is short, its safety, efficacy and long-term efficacy needs further observation and validation.